EPO and myelodysplastic syndrome: Patients with MDS/MPN-RS-T, often characterized by SF3B1 and JAK2 mutations and with a prognosis considered to be generally favorable to MDS with ring sideroblasts, are often treated with supportive care measures such as erythropoietin-stimulating agents and red cell transfusions for isolated anemia.